Latest Breaking News On - Bispecific engager technology platform - Page 1 : comparemela.com

Boan Biotech s Two Innovative Drugs Targeting Claudin 18 2 Granted ODD by FDA

YANTAI, China, Dec. 27, 2023 /PRNewswire/ Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the

United statesDou changlinInternational agency for research on cancerDrug administrationBispecific engager technology platformPhage display technology platformTechnology platformWorld health organizationBoan biotechOrphan drug designationAntibody drug conjugateInternational agencyChief operating officerNivolumab injectionHuman antibody transgenic mouseBispecifict cell engager technology platform

Boan Biotech Announces 2022 Financial Results, Showing Accelerated Innovation and Strong 225% Revenue Growth

YANTAI, CHINA - Media OutReach - 28 March 2023 - Boan Biotech (6955.HK) announced its 2022 financial results and recent business developments on March 27, 2023. 2022 business.

Hong kongJiang huaSino biopharmPhage display technology platformNational reimbursement drug listBispecific engager technology platformTechnology platformBoan biotechBiological license applicationMain boardHong kong stock exchangeShanghai hong kong stock connectShenzhen hong kong stock connectReimbursement drug listHuman antibody transgenic mousePhage display platform

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesJiang huaHong kongSteven yaoFu heliangKelly fungXiang jinjinSino biopharmaceuticalUbs ag hong kong branchErd technologyTechnology platformBispecific engager technology platformEssence international securities hong kongSecurities hong kongNumber of international offerH shares of the company

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Luye pharma groupTechnology platformPhage display technology platformBispecific engager technology platformWorld bispecific summitBoan biotechT cell engagerImprove safetyT cell based approachesHuman antibody transgenic mouseBispecifict cell engager technology platformBevacizumab injection